Table 4.
Beneficiaries/Issues According to Topic
Beneficiaries or Issues | ||||||||||||||||||||||||
Topic | Elderly | Children | Community | Primary | Hospital | Urban | Rural | Equity | Gender | Indigenous peoples/traditional medicine | Public private mix | TOTAL | ||||||||||||
A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | n = | B | |
Accessibility | 2 | 3 | 10 | 7 | 7 | 7 | 10 | 8 | 7 | 12 | 19 | 20 | 17 | 14 | 19 | 17 | 2 | 11 | 7 | 7 | 42 | 10 | ||
Community participation | 9 | 20 | 4 | 3 | 43 | 19 | 13 | 7 | 13 | 12 | 4 | 3 | 13 | 7 | 23 | 6 | ||||||||
costing & cost effectiveness | 13 | 3 | 13 | 2 | 38 | 6 | 13 | 4 | 13 | 3 | 13 | 2 | 8 | 2 | ||||||||||
Decentralisation/local health systems | 13 | 5 | 27 | 7 | 7 | 2 | 13 | 8 | 27 | 10 | 7 | 2 | 7 | 2 | 15 | 4 | ||||||||
Disease burden | 15 | 50 | 21 | 19 | 3 | 2 | 3 | 2 | 6 | 4 | 12 | 15 | 9 | 8 | 6 | 4 | 24 | 17 | 3 | 11 | 34 | 8 | ||
Economic policy and health | 14 | 10 | 43 | 8 | 14 | 2 | 29 | 4 | 7 | 2 | ||||||||||||||
Equity | 6 | 10 | 6 | 2 | 78 | 28 | 11 | 22 | 18 | 4 | ||||||||||||||
Financing | 39 | 17 | 4 | 4 | 9 | 5 | 39 | 18 | 4 | 2 | 4 | 2 | 23 | 6 | ||||||||||
Human resources | 29 | 9 | 35 | 15 | 6 | 2 | 6 | 4 | 18 | 8 | 6 | 11 | 17 | 4 | ||||||||||
Inform. Educ. & Communication | 21 | 8 | 7 | 2 | 7 | 2 | 14 | 8 | 14 | 5 | 36 | 11 | 14 | 3 | ||||||||||
Information systems | 25 | 4 | 38 | 7 | 13 | 2 | 13 | 3 | 13 | 2 | 8 | 2 | ||||||||||||
Insurance | 44 | 13 | 13 | 8 | 19 | 8 | 13 | 4 | 6 | 11 | 6 | 2 | 16 | 4 | ||||||||||
Management & Organization | 2 | 3 | 9 | 7 | 9 | 10 | 49 | 48 | 2 | 4 | 11 | 13 | 2 | 2 | 4 | 4 | 13 | 14 | 47 | 12 | ||||
Pharmaceutical policy & Mgmnt. | 17 | 5 | 33 | 8 | 8 | 3 | 25 | 6 | 8 | 2 | 8 | 11 | 12 | 3 | ||||||||||
Policy process | 50 | 6 | 17 | 4 | 33 | 4 | 6 | 1 | ||||||||||||||||
Programme evaluation | 2 | 10 | 22 | 24 | 2 | 2 | 17 | 17 | 5 | 4 | 12 | 19 | 2 | 3 | 2 | 2 | 2 | 2 | 32 | 30 | 41 | 10 | ||
Quality | 7 | 2 | 20 | 7 | 47 | 15 | 7 | 3 | 13 | 4 | 7 | 2 | 15 | 4 | ||||||||||
Research to evidence | 33 | 2 | 33 | 2 | 33 | 2 | 3 | 1 | ||||||||||||||||
Sector Analysis | 11 | 11 | 11 | 10 | 8 | 8 | 11 | 8 | 8 | 7 | 3 | 11 | 47 | 40 | 36 | 9 | ||||||||
None | 26 | 14 | 5 | 2 | 11 | 5 | 5 | 3 | 47 | 20 | 5 | 11 | 0 | 19 | 5 | |||||||||
n | 10 | 37 | 54 | 41 | 48 | 26 | 40 | 50 | 46 | 9 | 43 | 404 | 100 | |||||||||||
% | 2 | 100 | 9 | 100 | 13 | 100 | 10 | 100 | 12 | 100 | 6 | 100 | 10 | 100 | 12 | 100 | 11 | 100 | 2 | 100 | 11 | 100 |
A = % across the row ; B = % down the column